We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Pieris Pharmaceuticals Inc
26 own
47 watching
Current Price
$17.06
$-0.25
(-1.47%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
17M
52-Week High
41.76000
52-Week Low
6.20000
Average Volume
0.08M
Dividend Yield
--
P/E Ratio
--
Market Capitalization17M52-Week High41.7600052-Week Low6.20000Average Volume0.08MDividend Yield--P/E Ratio--What does the Pieris Pharmaceuticals Inc do?
Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. The company develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on the development of three drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; and PRS-343, a bispecific protein for oncology diseases. The company has collaboration agreements with Allergan, Inc.; Daiichi Sankyo Company Limited; Sanofi Group; Cadila Healthcare Limited (Zydus Cadila); Strides Arcolab Limited; and F.HoffmannLa Roche Ltd. It also has a strategic alliance with Servier Forge for the co-development of immuno-oncology. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Read More
How much money does Pieris Pharmaceuticals Inc make?
News & Events about Pieris Pharmaceuticals Inc.
Accesswire
1 year ago
BOSTON, MA / ACCESSWIRE / January 10, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other conditions, today announced that...
Accesswire
1 year ago
BOSTON, MA / ACCESSWIRE / November 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced...
Accesswire
1 year ago
BOSTON, MA / ACCESSWIRE / November 9, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that...
Accesswire
1 year ago
BOSTON, MA / ACCESSWIRE / November 1, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced...
Zolmax
2years ago
Woodline Partners LP bought a new stake in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS Get Rating) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 2,463,641 shares of the biotechnology companys stock, valued at approximately $9,313,000. Other large investors ...
Frequently Asked Questions
Frequently Asked Questions
What is Pieris Pharmaceuticals Inc share price today?
Can Indians buy Pieris Pharmaceuticals Inc shares?
How can I buy Pieris Pharmaceuticals Inc shares from India?
Can Fractional shares of Pieris Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Pieris Pharmaceuticals Inc stocks?
What is today’s traded volume of Pieris Pharmaceuticals Inc?
What is today’s market capitalisation of Pieris Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Pieris Pharmaceuticals Inc?
What percentage is Pieris Pharmaceuticals Inc down from its 52-Week High?
What percentage is Pieris Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$17.06
$-0.25
(-1.47%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.